Indeed, the French company's aim is to prove that regenerative medicine can be an alternative to liver transplantation.

Despite the complexity of the cell production chain and of cell-based drugs, GoLiver claims to have developed a specific process for producing hepatocytes entirely in vitro from pluripotent stem cells, which are able to self-renew in culture and differentiate themselves into many different cell types.

GoLiver’s ambition is to build a reliable, safe, reproducible, robust and economical production platform. The goal is to meet large-scale demand and deliver an innovative cell-based drug that is available to all patients, and at an acceptable cost for healthcare systems.